Holen Sie sich die Stockscreener-App
0.8899
4.14%
-0.0384
Handel nachbörslich:
.87
-0.0199
-2.24%
Renovorx Inc Aktie (RNXT) Neueste Nachrichten
Is RenovoRx (RNXT) stock creating a trading range | RenovoRx beats EPS by 2%, posts narrower Q4 lossBond Issuance - Newser
RenovoRx (RNXT) 2026 proxy: board elections, equity pool increase and auditor vote - Stock Titan
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET - Investing News Network
What RenovoRx plans to cover on its May 14 results call - Stock Titan
JonesTrading Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $8 - Moomoo
[EFFECT] RenovoRx, Inc. SEC Filing - Stock Titan
RenovoRx (RNXT) registers 15.96M resale shares; warrants carry $1.75–$1.93 strikes - Stock Titan
[SCHEDULE 13G/A] RenovoRx, Inc. Amended Passive Investment Disclosure - Stock Titan
RenovoRx (RNXT) price target increased by 18.52% to 8.16 - MSN
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting - Investing News Network
RenovoRx pancreatic cancer study tests more targeted chemo delivery - Stock Titan
RenovoRx (RNXT) price target decreased by 15.63% to 6.88 - MSN
RNXT (RenovoRx Inc.) narrowly tops Q4 2025 EPS estimates, falls slightly in immediate post-earnings trading.Expert Momentum Signals - Cổng thông tin điện tử Tỉnh Sơn La
RenovoRx Reports 2025 Results and Advances TIGeR-PaC Trial - TipRanks
RenovoRx (RNXT) registers 15.9M resale shares including warrants (S-3) - Stock Titan
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting - marketscreener.com
RenovoRx Inc Presents Clinical Data Supporting Targeted Chemotherapeutic Delivery Via Tamp Therapy Platform - marketscreener.com
Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting - The Manila Times
Pancreatic cancer scans show early response after artery-delivered chemo - Stock Titan
Fund Flows: Is RenovoRx Inc exposed to political risk2026 Trading Volume Trends & Real-Time Sentiment Analysis - baoquankhu1.vn
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET - ADVFN
Meme Stocks: Is RenovoRx Inc a defensive stockWeekly Trade Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement - ADVFN
Signal Recap: Whats the outlook for RenovoRx Incs sector2026 Sector Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
What is the short interest in RenovoRx (RNXT) Stock | Price at $0.97, Up 3.41%Stock Screening - Newser
RenovoRx receives Japanese patent for RenovoCath device By Investing.com - Investing.com Australia
RNXT: HC Wainwright Reiterates Buy Rating and $3.00 Price Target - GuruFocus
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum - Bitget
RenovoRx receives Japanese patent for RenovoCath device - Investing.com
RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum - Investing News Network
Cancer drug-delivery device wins Japan patent allowance as RenovoRx expands - Stock Titan
RenovoRx (RNXT) CCO awarded 128,550 options at $0.98 exercise price - Stock Titan
RenovoRx (RNXT) CMO granted 621,727 options vesting through 2030 - Stock Titan
Stock Recap: How does RenovoRx Inc perform in inflationary periods2026 Historical Comparison & Risk Managed Investment Entry Signals - baoquankhu1.vn
Will RenovoRx (RNXT) Stock Hit New Highs | Price at $0.93, Down 4.90%Community Driven Stock Picks - Newser
RenovoRx, Inc. Appoints Ramtin Agah, M.D. As Executive Chairman , Effective February 27, 2026 - marketscreener.com
RNXT Stock Analysis: RenovoRx Inc. biotech trades near 1 dollar on mild daily gain - Newser
RNXT Technical Analysis & Stock Price Forecast - Intellectia AI
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI) and RenovoRx (RNXT) - The Globe and Mail
RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 - Taiwan News
Street Watch: How does RenovoRx Inc perform in inflationary periods2026 Price Action Summary & Reliable Price Breakout Signals - baoquankhu1.vn
RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 - Investing News Network
RNXT SEC FilingsRenovorx Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RenovoRx Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RenovoRx earnings beat, revenue fell short of estimates By Investing.com - Investing.com Canada
RenovoRx Reports Solid First Full Year of RenovoCath Commercialization - National Today
RenovoRx Inc (RNXT) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Trade Recap: What chart patterns are forming on RenovoRx IncMarket Performance Summary & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Published on: 2026-03-31 14:32:17 - baoquankhu1.vn
RNXT: 2026 revenue is projected to triple as commercial site expansion accelerates and funding strengthens - TradingView
1.77%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):